Beacon Trusteeship Discloses 5.44% Equity Encumbrance in Symbiotec Pharmalab
Symbiotec Pharmalab Ltd 路 Acquisition/ Disposal of Shares 路 11 Sept 2026, 6:00 pm
Beacon Trusteeship Discloses 5.44% Equity Encumbrance in Symbiotec Pharmalab Beacon Trusteeship Limited, acting as debenture trustee for NCDs issued by Satwani Holdings (India) Private Limited, created an encumbrance over 3,493,464 equity shares of Symbiotec Pharmalab Limited. This represents 5.44% of total share capital and 5.43% of diluted share capital. The pledged shares, created between 8th Sep'26 and 9th Sep'26, comprise holdings from promoter group members: Satwani Holding LLP (3.47%), Kashish Satwani (0.78%), Anil Satwani (0.70%), and Sushil Satwani (0.49%) to secure debt obligations under the debenture trust deed.
Original exchange filing (PDF)
More announcements from Symbiotec Pharmalab Ltd
- Intimation regarding change in Corporate Identification Number (CIN) and Listing Status of the Company. 路 17 Nov 2026
- Transcript of the Earnings conference call for the Analysts and Investors for the Quarter and Half year ended 路 12 Nov 2026
- Pursuant to Regulation 30(6) read with Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements), Regulations, 2015, as amended from time .... 路 12 Nov 2026
- Pursuant to Part A of Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Audio recording of Conference Call for Analysts and Investors held on November .... 路 06 Nov 2026
- Symbiotec Signs 10 Year take or Pay Agreement to Manufacture Fermentation based alternative protein for EU Innovator 路 06 Nov 2026
- The Monitoring Agency report issued by the CARE Edge Ratings, Monitoring Agency, appointed by the Company for the utilisation and application of funds raised through the IPO of the Company .... 路 06 Nov 2026
- The Investor release being issued by the company, for the quarter and half year ended September 30, 2026 路 06 Nov 2026
- Pursuant to regulations 30 of the SEBI Listing Regulations, Investor Presentation on the Unaudited Standalone and Consolidated Financial Results for the Quarter and Half Year ended September 30, 2026. 路 06 Nov 2026
